X
XORTX Therapeutics Inc. (XRTX)
NCM – Real Time Price. Currency in USD
0.38
+0.03 (7.55%)
At close: Mar 27, 2026, 4:00 PM EDT
0.35
-0.03 (-7.12%)
After-hours: Mar 27, 2026, 6:15 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.38
+0.03 (7.55%)
At close: Mar 27, 2026, 4:00 PM EDT
0.35
-0.03 (-7.12%)
After-hours: Mar 27, 2026, 6:15 PM EDT
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
| Name | Position |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Ms. Charlotte May | Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | 20-F | tmb-20251231x20f.htm |
| 2026-03-19 | 6-K | f6k_031926.htm |
| 2026-03-13 | 6-K | f6k_031326.htm |
| 2026-03-05 | 6-K | f6k_030526.htm |
| 2026-03-03 | 6-K | f6k_030326.htm |
| 2026-01-02 | 6-K | f6k_010226.htm |
| 2025-11-17 | 6-K | f6k_111525.htm |
| 2025-10-31 | 6-K | tm2529364d1_6k.htm |
| 2025-10-29 | 6-K | f6k_102925.htm |
| 2025-10-21 | 6-K | f6k_102125.htm |